Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00642655 | Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation | PHASE1 | COMPLETED | 20 | — | — | Sep 1, 2005 | May 1, 2007 | Mar 25, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| IVIG and Rituximab | DRUG | IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22 |
Inclusion Criteria: * Patients eligible for the study will be those who have anti-HLA antibody (Panel Reactive Antibody \[PRA\]) of \>30% and are eligible for transplantation at Cedars-Sinai Medical Center. We currently anticipate entering 20 patients over the course of the study. We currently have...